GROG

Compte Twitter officiel du GROG, Groupe de Recherche en Obstétrique et Gynécologie.

[GROG @GROG_StudyGroup]

Migration sur Bluesky ---> https://t.co/597VbdUyYg

[GROG @GROG_StudyGroup]

Among participants receiving oxytocin in early labour, discontinuing oxytocin when the active phase is reached does not clinically or statistically significantly reduce neonatal morbidity compared with continuous oxytocin. @TheLancet @LeRayGO @audeglt https://t.co/zQuEYBKtZh

[GROG @GROG_StudyGroup]

The early use of intrauterine balloon tamponade did not reduce the incidence of severe postpartum hemorrhage compared with its use after the failure of second-line uterotonic treatment and before recourse to invasive procedures @AJOG_thegray https://t.co/DIzxXgNX9M

[Camille Le Ray @LeRayGO]

@APHP @Inserm @univ_paris_cite Fière de cet essai et de cette belle publication avec @audeglt et le @GROG_StudyGroup

[GROG @GROG_StudyGroup]

Pluriannual meeting of the GROG Study Group in Paris. Great research projects in perspective. #Obstetrics #Team #Research

[GROG @GROG_StudyGroup]

Our correspondence in The Lancet about FRENCH-ARRIVE after serious, evidence-free, and false accusation of unethical research. With the support of Ben W Mol and colleagues for the need for appropriate language in the debate on medicalisation of pregnancy.

[GROG @GROG_StudyGroup]

Several members of the GROG study group are present at the 6th European Congress on Intrapartum Care to present their work #ECIC2023 #Belgrade 👏

[GROG @GROG_StudyGroup]

Some of the GROG study group (Groupe de Recherche en Obstétrique et Gynécologie) members at the #SMFM23 meeting to proudly represent French research in obstetrics!

[GROG @GROG_StudyGroup]

Arrêt de l'#oxytocine pendant la phase active du 1er stade du travail, l’essai randomisé français STOPOXY avec près de 2500 patientes incluses (1192 vs 1175) : pas de différence de morbidité néonatale, du mode d'accouchement, des indications de césarienne #SMFM2023 👏 @audeglt

[GROG @GROG_StudyGroup]

Discontinuation of #oxytocin during the active first stage of #labor, the French RCT STOPOXY which included almost 2500 patients (1192 vs 1175): no difference in neonatal morbidity, mode of delivery, indications for C/S. #SMFM2023 👏 @audeglt

[GROG @GROG_StudyGroup]

New article from the TRAAP2 Study Group : « Surgeons’ gender was not associated with maternal morbidity after a cesarean delivery ». #TRAAP2 https://t.co/cNjvrPZOMC @CHUBordeaux @Epope_Inserm @GROG_StudyGroup @JAMASurgery @JAMANetwork

[EPOPé @Epope_Inserm]

In #TwinPregnancies, the risk of severe #PostPartumHemorrhage increases from 2% for sum of twins' birthweights below 3000 grams to 9% for sum exceeding 6500g (i.e. 35% risk increase for +500g in sum of birthweigths) #JUMODA @greenjrnl @GROG_StudyGroup https://t.co/ldWvDVMkW5

[EPOPé @Epope_Inserm]

📣 🚨 Le rapport de l’Enquête Nationale Périnatale 2021 est sorti aujourd’hui #ENP #perinatalite #grossesse #accouchement #naissances
Le rapport complet est disponible sur le site https://t.co/jovH5oM222

[AJOG @AJOG_thegray]

Alternative to intensive management of the active phase of the second stage of labor: a multicenter randomized trial (PASST trial) among nulliparous women with an epidural - A, Intervention (moderate pushing) group. B, Control (intensive pushing) group. https://t.co/IfdNfWGQfz

[Camille Le Ray @LeRayGO]

Publication PASST trial @GROG_StudyGroup Alternative to intensive management of the active phase of the second stage of labor: a multicenter randomized trial among nulliparous women with an epidural https://t.co/ltHkxGTzgG

[Assistance Publique – Hôpitaux de Paris (AP-HP) @APHP]

Premiers résultats de l’essai BETADOSE sur une réduction de dose de 50 % du traitement anténatal par la bétaméthasone donné pour prévenir les complications de la prématurité : https://t.co/OqlTCYU2J1

@HopRobertDebre | @Inserm | @univ_paris_cite

[GROG @GROG_StudyGroup]

Neonatal outcomes for women at risk of preterm delivery given half dose versus full dose of antenatal betamethasone: a randomised, multicentre, double-blind, placebo-controlled, non-inferiority trial. ⁦@TheLancet⁩ https://t.co/uNkGdhnE3J

[GROG @GROG_StudyGroup]

https://t.co/jWgf84kYzy

[GROG @GROG_StudyGroup]

Among women with a multiple pregnancy and cesarean delivery, prophylactic tranexamic acid did not reduce the incidence of any blood loss-related outcomes. #TRAAP2SecondaryAnalysis @AJOG_thegray

[GROG @GROG_StudyGroup]

Planned cesarean delivery for very preterm twins is not associated with better survival to discharge without severe neonatal morbidity than planned vaginal delivery. @greenjrnl #Preterm #TwinPregnancy #NeonatalMorbidity #JUMODA https://t.co/6ORei1piyZ